Skip to main content
Lotus Pharm logo

Lotus Pharm — Investor Relations & Filings

Ticker · 1795 ISIN · TW0001795003 LEI · 984500BEECDBC04KP716 TW Manufacturing
Open in API
Filings indexed 2,732 across all filing types
Latest filing 2022-08-08 Investor Presentation
Country TW Taiwan
Listing TW 1795

About Lotus Pharm

http://www.lotuspharm.com.tw

Lotus Pharmaceutical Co., Ltd. is a global specialty organization focused on the development, manufacturing, and commercialization of high-barrier generic and specialty medicines. The company specializes in complex generics, with a primary focus on oncology, immunology, and addiction treatment. Its portfolio includes technically demanding products such as Lenalidomide, Suboxone, Nintedanib, and Vinorelbine, as well as an advancing pipeline of biosimilars and 505(b)(2) oncology candidates. Utilizing an integrated R&D and manufacturing platform, the company executes a "2x2" growth strategy centered on dual market expansion and product diversification. Its commercial footprint spans over 90 markets globally, maintaining a strong presence in the Asia-Pacific region and the United States. The company prioritizes high technical entry barriers and cost-effective therapeutic solutions to improve global patient access to essential medications.

Recent filings

Filing Released Lang Actions
本公司將召開線上法人說明會
Investor Presentation Classification · 95% confidence The document is a short announcement (722 characters) about the company scheduling an online investor conference call (法人說明會) to explain financial and operational status. It provides the date, time, and access details for the call but does not contain any financial data or detailed report content. This matches the description of an Investor Presentation (IP) announcement or a Call Transcript (CT) announcement. However, since it is announcing the event rather than providing the transcript, and it is a notice about a scheduled investor presentation, the best fit is Investor Presentation (IP). The document is not a transcript itself, nor a full financial report, nor a regulatory filing or report publication announcement. Therefore, the classification is Investor Presentation (IP) with high confidence.
2022-08-08 Chinese
公告本公司訂定資本公積發放現金除息基準日
Notice of Dividend Amount Classification · 100% confidence The document is a short announcement from a company regarding the declaration of a cash dividend from capital surplus, including key dates such as the ex-dividend date, record date, and payment date. It does not contain financial statements or detailed financial analysis but rather dividend payment details. The document length is only 684 characters, indicating it is a brief announcement rather than a full report. Therefore, it fits the category of Notice of Dividend Amount (DIV).
2022-07-19 Chinese
111年06月內部人持股異動(事後)
Director's Dealing Classification · 95% confidence The document consists of detailed tables listing shareholdings and changes in share ownership by insiders, including directors, managers, and major shareholders. It includes data on shares held, increases, decreases, and trust shares. The content is focused on insider share transactions and holdings rather than financial results, management changes, or regulatory announcements. There is no indication of it being a full financial report, earnings release, or management discussion. The document is not a proxy statement or voting results announcement. Given the detailed insider shareholding data, this fits the definition of Director's Dealing (DIRS), which reports personal share transactions by company directors and executives (insider trades). The document length is substantial and contains actual data, not just an announcement or certification. Therefore, the classification is DIRS with high confidence.
2022-07-18 Chinese
111年06月董事會成員及持股
Director's Dealing Classification · 95% confidence The document contains detailed tabular data about shareholdings of company insiders, including directors, managers, and major shareholders. It lists the number of shares held, pledged shares, and related percentages. The content focuses on insider shareholdings and their changes, which aligns with disclosures about personal share transactions or holdings by company directors and executives. There is no indication of financial results, meeting materials, or regulatory announcements unrelated to insider holdings. The document length is 4359 characters, which is sufficient for a detailed insider shareholding report. Therefore, the document fits best under the category of Director's Dealing (DIRS).
2022-07-18 Chinese
111年年報及股東會資料 — 2022_1795_20220630F14.pdf
Regulatory Filings
2022-07-12 Chinese
111年年報及股東會資料 — 2022_1795_20220630F05.pdf
Regulatory Filings
2022-07-12 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.